Updated Efficacy Results From the BIRCH Study: First-Line Atezolizumab Therapy in PD-L1-Selected Patients With Advanced NSCLC
Por:
Carcereny, E, Felip, E, Reck, M, Patel, J, Heist, R, Balmanoukian, A, Chow, L, Paz-Ares, L, Qiu, J, Coleman, S, Mocci, S, Sandler, A, Kurata, T and Shepherd, F
Publicada:
1 nov 2017
Resumen:
Filiaciones:
:
Germans Trias I Pujol Hosp Badalona, Catalan Inst Oncol Badalona, Badalona, Spain
Felip, E:
Vall dHebron Inst Oncol, Barcelona, Spain
Reck, M:
German Ctr Lung Res DZL, Airway Res Ctr North ACRN, Lung Clin Grosshansdorf, Grosshansdorf, Germany
Patel, J:
Univ Chicago, Chicago, IL 60637 USA
Heist, R:
Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA
Balmanoukian, A:
Angeles Clin & Res Inst, Los Angeles, CA USA
Chow, L:
Univ Complutense, Hosp Univ 12 Octubre, Med Oncol Dept, Madrid, Spain
Paz-Ares, L:
CNIO, Madrid, Spain
Qiu, J:
Genentech Inc, San Francisco, CA USA
Coleman, S:
Genentech Inc, San Francisco, CA USA
Mocci, S:
Genentech Inc, San Francisco, CA USA
Sandler, A:
Genentech Inc, San Francisco, CA USA
Kurata, T:
Kansai Med Univ, Hirakata Hosp, Osaka, Japan
Shepherd, F:
Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
|